Hypoxanthine-maleic acid eutectic crystal as well as preparation method and application thereof
By forming co-crystals with hypoxanthine and maleic acid, the problem of low solubility of hypoxanthine is solved, significantly improves its solubility and anti-obesity effect, and provides a more effective drug preparation.
Patent Information
- Application Number
- CN202411130647.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
AI Technical Summary
The low solubility of hypoxanthine limits its bioavailability in drug applications, especially in anti-obesity.
By forming eutectics with maleic acid, hypoxanthine-maleic acid eutectics are prepared by liquid-assisted grinding or solution evaporation to improve their solubility and enhance their anti-obesity effect.
It significantly improves the solubility and anti-obesity effect of hypoxanthine, provides better drug preparations, and has good practical application value.
Smart Images

Figure CN119019398A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical co-crystals, and specifically relates to a hypoxanthine-maleic acid co-crystal and a preparation method and application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Hypoxanthine (6-hydroxypurine) is a common purine compound having a highly active 6-hydroxyl functional group, and its structural formula is shown in Formula I.
[0004]
[0005] Hypoxanthine is involved in regulating certain physiological functions of the human body, such as promoting fat decomposition, reducing the weight of mice, etc. However, due to its low solubility, its application is limited. Therefore, it is of great significance to develop a method to improve the solubility of hypoxanthine. Summary of the invention
[0006] In order to overcome the deficiencies of the prior art, the object of the present invention is to provide a hypoxanthine-maleic acid cocrystal and a preparation method and application thereof. The hypoxanthine-maleic acid cocrystal provided by the present invention has high solubility and has an anti-obesity effect.
[0007] In order to achieve the above object, the technical solution of the present invention is:
[0008] In a first aspect of the present invention, there is provided a hypoxanthine-maleic acid cocrystal, wherein the asymmetric unit is composed of two hypoxanthine ions and two maleic acid ions;
[0009] The space group of the hypoxanthine-maleic acid eutectic is P2 1 / c, monoclinic system, the specific unit cell parameters are: α=90°, β=95.862(2)°, γ=90°.
[0010] The molecular structures of the hypoxanthine molecule (HYP), maleic acid molecule (MAL), hypoxanthine ion (HYP) and maleic acid ion (MAL) are shown below:
[0011]
[0012] The second aspect of the present invention provides a method for preparing the hypoxanthine-maleic acid cocrystal, comprising the following steps:
[0013] It is prepared using hypoxanthine and maleic acid as raw materials by liquid-assisted grinding.
[0014] The third aspect of the present invention provides a method for preparing the hypoxanthine-maleic acid cocrystal, comprising the following steps:
[0015] It is prepared using hypoxanthine and maleic acid as raw materials and the solution evaporation method.
[0016] The fourth aspect of the present invention provides a use of the hypoxanthine-maleic acid co-crystal or the hypoxanthine-maleic acid co-crystal prepared by the preparation method in the preparation of a hypoxanthine pharmaceutical preparation.
[0017] The beneficial effects of the present invention are:
[0018] The present invention improves the physicochemical properties of hypoxanthine by preparing a crystalline drug. By adding maleic acid to hypoxanthine to prepare a hypoxanthine-maleic acid cocrystal drug, the solubility of hypoxanthine can be significantly improved, and the anti-obesity effect thereof can be improved, so the present invention has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0020] Figure 1 is the X-ray powder diffraction pattern of HYP-MAL prepared in Example 1;
[0021] Figure 2 X-ray powder diffraction patterns, including (a) HYP, (b) MAL, (c) HYP and MAL mixture, and (d) HYP-MAL simulation;
[0022] Figure 3 for the asymmetric unit and hydrogen bonding contacts of HYP-MAL;
[0023] Figure 4(a) is the DSC graphs of HYP, HYP-MAL and MAL;
[0024] Figure 4(b) is the TGA graph of HYP, HYP-MAL and MAL;
[0025] Figure 5 The infrared spectra of HYP, HYP-MAL and MAL;
[0026] Figure 6 (a) shows the solubility of HYP and HYP-MAL at different pH and temperature (n=3);
[0027] Figure 6(b) shows the powder dissolution curves of HYP and HYP-MAL in PBS (37°C);
[0028] Figure 7 (a) shows the body weight and changes of mice in the model group during the drug administration period (n>6);
[0029] Figure 7(b) shows the body weight and changes of mice in the drug administration group during the drug administration period (n>6);
[0030] Figure 8 The effects of HYP-MAL on the internal organs of mice (n>6), including (a) liver, (b) thymus, (c) epididymal fat, and (d) perirenal fat; Note: Mean values that do not share a common letter are significantly different among the groups (p<0);
[0031] Fig. 9 These are the adipose tissue section images of mice (×200), among which (a) is NCG, (b) is HFD, (c) is HYP-L, (d) is HYP-M, (e) is HYP-MAL-PML, (f) is HYP-MAL-PMM, (g) is HYP-MAL-L, (h) is HYP-MAL-M, (i) is HYP-MAL-H, and (j) is LC. DETAILED DESCRIPTION
[0032] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the reagent company; the reagents and consumables used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0033] As mentioned above, the solubility of hypoxanthine in both water and PBS is relatively low, and its bioavailability is limited.
[0034] In view of this, the present invention provides a cocrystal formed by hypoxanthine (HYP) and maleic acid (MAL). Characterization and physical and chemical property tests using Cu-Kα show that the X-ray diffraction spectrum has a sharp diffraction peak, and the prepared cocrystal significantly improves the solubility of hypoxanthine, making up for the shortcomings of the prior art. In addition, compared with hypoxanthine, the drug cocrystal can improve the anti-obesity effect.
[0035] Specifically, in a typical embodiment of the present invention, a hypoxanthine-maleic acid cocrystal is provided, wherein the asymmetric unit is composed of two hypoxanthine ions and two maleic acid ions;
[0036] The space group of the hypoxanthine-maleic acid eutectic is P2 1 / c, monoclinic system, the specific unit cell parameters are: α=90°, β=95.862(2)°, γ=90°.
[0037] The present invention selects organic acids containing carboxyl groups as ligands because carboxylic acid compounds have greater solubility. Hypoxanthine and dozens of organic acids (coumaric acid, succinic acid, trans-2-hydroxycinnamic acid, L-malic acid, L-tartaric acid, malonic acid, 1,3,5-trihydroxybenzoic acid, citric acid, hippuric acid, nicotinic acid, oxalic acid, nicotinamide, acetylsalicylic acid, L-glutamic acid, γ-aminobutyric acid, L-valine, lauric acid, L-proline, L-leucine, vanillin, ethylenediaminetetraacetic acid, vitamin C, caffeic acid, etc.) are screened for eutectic / salts by grinding, solvent volatilization, and suspension methods, and single crystal cultivation is performed, and finally hypoxanthine-maleate (HYP-MAL) is obtained, and single crystals are obtained. The results show that salt formation can improve the solubility of hypoxanthine, and its weight loss effect on nutritionally obese mice is studied. Its structure was determined by single crystal X-ray diffraction (SXRD) and characterized by powder X-ray diffractometer, thermogravimetric analyzer, differential scanning calorimeter and Fourier transform infrared spectrometer. In addition, the present invention also assisted in simulation and calculation of molecular surface electrostatic potential, molecular orbital (HOMO and LUMO) and Hirshfeld surface analysis to explain the salt formation mechanism. The present invention also evaluated the solubility of the salt in three media. At the same time, a mouse obesity model was established to prove that HYP-MAL has an anti-obesity effect on nutritionally obese mice.
[0038] In some examples of this embodiment, the X-ray powder diffraction pattern of the hypoxanthine-maleic acid cocrystal with Cu-Kα rays has characteristic diffraction peaks at the following 2θ angles: 7.7±0.20°, 9.9±0.20°, 13.4±0.20°, 13.9±0.20°, 16.5±0.20°, 17.2±0.20°, 18.7±0.20°, 23.1±0.20°.
[0039] In some examples of this embodiment, the Cu-Kα-ray X-ray powder diffraction pattern of the hypoxanthine-maleic acid cocrystal is as follows: Figure 1 As shown, the error is within ±0.20°.
[0040] In some examples of this embodiment, the differential scanning calorimetry curve of the hypoxanthine-maleic acid cocrystal shows endothermic peaks at 186.83±3.0°C and 404.83±3.0°C.
[0041] In some examples of this embodiment, the differential scanning calorimetry spectrum of the hypoxanthine-maleic acid cocrystal is shown in FIG4( a ), and the thermogravimetric analysis spectrum is shown in FIG4( b ).
[0042] In some embodiments of this embodiment, the Fourier transform infrared spectrum of the hypoxanthine-maleic acid cocrystal is 3135.87 cm -1 There is a characteristic peak of NH in hypoxanthine at 1671.91 cm -1 There is a characteristic peak of C=O in maleic acid.
[0043] In some examples of this embodiment, the Fourier transform infrared spectrum of the hypoxanthine-maleic acid cocrystal is as follows: Figure 5 shown.
[0044] In another specific embodiment of the present invention, a method for preparing the above-mentioned hypoxanthine-maleic acid cocrystal is provided, comprising the following steps:
[0045] It is prepared using hypoxanthine and maleic acid as raw materials by liquid-assisted grinding.
[0046] Wherein, the molar ratio of hypoxanthine to maleic acid is (0.9-1.1):(0.9-1.1), preferably 1:1.
[0047] Wherein, the liquid-assisted grinding method comprises the following steps:
[0048] ball-milling hypoxanthine and maleic acid in a solvent to obtain hypoxanthine-maleic acid cocrystal;
[0049] The solvent is selected from one or more of water, alcohols, ketones, esters, alkanes, aromatic hydrocarbons and halogenated hydrocarbons.
[0050] Wherein, the solvent is selected from one or more of water, methanol, ethanol, isopropanol, ethyl acetate, acetone, methyl ethyl ketone, n-hexane and n-heptane.
[0051] In a specific embodiment of the present invention, the solvent is methanol. The ball milling can be performed in a ball milling jar.
[0052] 0.25 mmol HYP and 0.25 mmol MAL were mixed with 30 μL methanol in a ball mill, and ground with two 5-10 mm (preferably 7 mm) stainless steel balls at a frequency of 25-30 Hz (preferably 26 Hz) for 5 min.
[0053] In another specific embodiment of the present invention, a method for preparing the above-mentioned hypoxanthine-maleic acid cocrystal is provided, comprising the following steps:
[0054] It is prepared using hypoxanthine and maleic acid as raw materials and the solution evaporation method.
[0055] Wherein, the molar ratio of hypoxanthine to maleic acid is (0.9-1.1):(4.9-5.1), preferably 1:5.
[0056] Wherein, the solution evaporation method comprises the following steps:
[0057] Recrystallize hypoxanthine and maleic acid in a solvent, and let stand to obtain hypoxanthine-maleic acid cocrystal;
[0058] The solvent is selected from one or more of water, alcohols, ketones, esters, alkanes, aromatic hydrocarbons and halogenated hydrocarbons.
[0059] Wherein, the solvent is selected from one or more of water, methanol, ethanol, isopropanol, ethyl acetate, acetone, methyl ethyl ketone, n-hexane and n-heptane.
[0060] In a specific embodiment of the present invention, the solvent is a mixed solution of methanol, acetone and water, and the volume ratio of methanol to acetone is preferably 1:1.
[0061] Weigh HYP and MAL and dissolve them in a mixed solvent containing 10 mL of methanol and 10 mL of acetone, heat and stir for 4 h, add a small amount of pure water after filtering, and incubate at room temperature for about 20-30 days to finally obtain high-quality crystals.
[0062] In another specific embodiment of the present invention, there is provided use of the above hypoxanthine-maleic acid co-crystal or the hypoxanthine-maleic acid co-crystal prepared by the above preparation method in the preparation of hypoxanthine pharmaceutical preparations.
[0063] The hypoxanthine pharmaceutical preparation has the effects of promoting fat decomposition and weight loss.
[0064] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0065] Example 1
[0066] This embodiment provides a method for preparing hypoxanthine-maleic acid cocrystal based on liquid-assisted grinding: HYP (34.03 mg, 0.25 mmol) and MAL (29.02 mg, 0.25 mmol) were mixed with 30 μL of methanol in a ball mill, and ground with two 7 mm stainless steel balls at a frequency of 26 Hz for 5 min to obtain a cocrystal product HYP-MAL.
[0067] Ultrafine powders were obtained by liquid-assisted grinding. Powder X-ray diffraction (PXRD) was used to confirm the formation of HYP-MAL. The PXRD pattern of HYP-MAL is shown in Figure 2. Figure 1 shown.
[0068] Example 2
[0069] This embodiment provides a method for preparing hypoxanthine-maleic acid cocrystal based on solution evaporation method: HYP (13.61 mg, 0.10 mmol) and MAL (58.04 mg, 0.50 mmol) were weighed and dissolved in a mixed solvent containing 10 mL of methanol and 10 mL of acetone, heated and stirred for 4 h, filtered, added with a small amount of purified water, and incubated at room temperature for about 20-30 days to obtain the cocrystal product HYP-MAL.
[0070] Ultrafine powder was obtained by solution evaporation method. The PXRD pattern of the obtained eutectic is similar to Figure 1 Consistent.
[0071] Performance Testing
[0072] 1. Characterization of Salt
[0073] (1) Powder X-ray Diffraction (PXRD) All PXRD measurements were performed using a MiniFlex600 powder diffractometer (Rigaku) with the following experimental parameters: tube voltage and current set to 40 kV and 30 mA; Cu Kα radiation (0.15405 nm) in the 2θ range (3–50°) at room temperature. The step size was 0.02° and the scan speed was 8° / min.
[0074] (2) Single crystal X-ray diffraction (SXRD) Unit cell parameters and intensity data were recorded at 293 K on an XtaLAB Synergy-S diffractometer (Rigaku Oxford Diffraction) equipped with a HyPix-6000HE hybrid photon counting (HPC) detector and an Oxford Cryosystems Cryostream Plus 800 open N 2 Cooling equipment.
[0075] (3) Synchronous Thermal Analysis (TG / DSC) Thermal analysis was performed using a TGA / DSC3+ (Mettler-Toledo, Switzerland). The sample was placed in a ceramic crucible and placed in a TG furnace. The analysis was started at 303.15 K and heated at 10 K min under nitrogen. -1 The furnace is heated at a rate of 1.5 % until the final temperature reaches 723.15 K.
[0076] (4) Fourier transform infrared spectroscopy (FTIR) was performed using KBr pellets and recorded on an Agilent Cary 630 FT-IR spectrometer at 400–4000 cm -1 range of the infrared spectrum.
[0077] (5) High performance liquid chromatography (HPLC): Agilent 1260 high performance liquid chromatograph was used for analysis with a reverse phase column (C18, 250 mm × 4.6 mm, filler particle size: 5 μm); mobile phase configuration: 1 ± 0.02 mL of phosphoric acid was added to a 1000 mL volumetric flask, 100 mL of methanol (HPLC) was added, and the mixture was diluted to the mark with deionized water, and bubbles were removed by ultrasound. The injection volume was 2 μL, the mobile phase flow rate was 0.6 mL / min, the separation column temperature was maintained at 30 °C, and the UV detection wavelength was set to 250 nm.
[0078] 2. Equilibrium solubility and powder dissolution determination
[0079] (1) HYP and HYP-MAL were ground separately and passed through standard sieves for solubility and powder dissolution tests.
[0080] (2) Drawing of hypoxanthine standard curve
[0081] Accurately weigh 10.0 mg hypoxanthine and dissolve it in 50 mL water, dilute to 250 mL, dilute with mobile phase, measure by HPLC, plot the relationship between content and peak area, and obtain the hypoxanthine standard curve, Y = 7457.2X-4.1093, R 2 =0.999, where Y represents the peak area, X represents the amount of hypoxanthine compound, μg, and R is the relative standard deviation.
[0082] (3) Determination of equilibrium solubility of HYP and HYP-MAL
[0083] Add excess sample to 10 mL of water (pH=6.4) at 25°C and 10 mL of PBS (pH=1.2, 7.4) at 37°C, respectively, stir at constant temperature for 24 hours, pass the slurry through a 0.22 μm filter, dilute appropriately, and measure three times in parallel for HPLC measurement.
[0084] (4) HYP and HYP-MAL powder dissolution test
[0085] The powder dissolution rate was carried out in PBS (pH = 7.4). Excess HYP and HYP-MAL samples were added to 40 mL PBS at 37 ° C, stirred (100 rpm), and samples were taken at 1, 3, 5, 8, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min. 1 mL of solution was taken out and filtered through a 0.22 μm filter at a preset time, and then 1 mL of fresh dissolution medium was added. All samples weighed 200 mg. The filtrate was appropriately diluted and the concentration was measured by HPLC.
[0086] 3. Density functional theory research
[0087] Hirshfeld surface analysis was performed to characterize the contribution (%) of various intermolecular contacts in the supramolecule. Hirshfeld surface plots and 2D fingerprint plots were generated using CrystalExplorer 21.5. Extensive density functional theory (DFT) calculations were used to understand and predict intermolecular interaction forces. In this study, the B3LYP functional was used to perform all calculations. The 6-31G(d) basis set was used for all hydrogen atom geometry optimizations and monoenergetic calculations, respectively. The Gaussian 16 software package was used for all calculations. Electrostatic potential (ESP), molecular orbitals (HOMO and LUMO) were calculated using Multiwfn software and visualized by VMD software.
[0088] 4. Animal experiments
[0089] (1) ICR male mice (Beijing Weitonglihua Experimental Animal Technology Co., Ltd.), 3 weeks old, weighing 18-22 g, license number: SCXK (Beijing) 2021-0006.
[0090] (2) ICR male mice were raised in the Animal Experiment Center of Shandong University of Traditional Chinese Medicine (Shandong University of Traditional Chinese Medicine has a pharmaceutical public service platform and an experimental animal center platform, and has animal ethics experiment qualifications, so Shandong University of Traditional Chinese Medicine was commissioned to conduct the in vivo evaluation of the multi-component solid system). Relative humidity was (55±1)%, temperature was (23±1)°C, and the light and dark time were about 12h each. They were allowed to drink water freely every day and received ordinary feed for adaptive feeding.
[0091] After one week of adaptive feeding, 10 mice were randomly selected as the blank group and fed with ordinary feed throughout the experiment. After adaptive feeding, the remaining mice were fed with a mixture of high-fat feed and ordinary feed for 1 week, and then continued to be fed with high-fat feed until the end of the experiment. After 4 weeks, mice in the high-fat feed group were randomly selected to measure total cholesterol (TC), total triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C), and animals that met the requirements were enrolled in the experiment.
[0092] Beijing Keao Xieli Feed Company's hyperlipidemia model feed formula:
[0093] Basic feed + 15% lard + 20% sucrose + 1.2% cholesterol + 0.2% sodium cholate, etc. The specific formula is shown in Table 1.
[0094] Table 1 High fat diet formula
[0095]
[0096] (3) Grouping and Dosage
[0097] 1) Blank group (NCG)
[0098] After confirming that the model was successful, the obese model mice were randomly divided into 9 groups.
[0099] 2) Model group (HFD)
[0100] 3) Positive control group (L-carnitine 100 mg / kg, LC)
[0101] 4) HYP low-dose group (20 mg / kg, HYP-L)
[0102] 5) HYP medium dose group (40 mg / kg, HYP-M)
[0103] 6) HYP-MAL physical mixture low-dose group (37.06 mg / kg, HYP-MAL-PML, where "PM" in PML means that HYP and MAL are physically mixed, and "L" means low dose)
[0104] 7) Medium dose group of HYP-MAL physical mixture (74.12 mg / kg, HYP-MAL-PMM, where "PM" in PMM means that HYP and MAL are physically mixed, and "M" means medium dose)
[0105] 8) HYP-MAL low-dose group (37.06 mg / kg, HYP-MAL-L)
[0106] 9) HYP-MAL medium dose group (74.12 mg / kg, HYP-MAL-M)
[0107] 10) HYP-MAL high-dose group (111.18 mg / kg, HYP-MAL-H)
[0108] (HYP-MAL below all represent hypoxanthine-maleic acid eutectic)
[0109] Ensure that the number of animals in each group is no less than 8.
[0110] During the experiment, except for the feeding and oral administration of drugs (the blank group was gavaged with an equal amount of normal saline), the other conditions of the high-fat group and the blank group remained the same. The body weight of the animals was measured every week, and the food intake of mice in different groups was recorded. The body length of the mice was measured before and after drug administration.
[0111] (4) Sample collection
[0112] Four weeks after modeling, blood was collected from the eye sockets to detect the levels of TG, TC, and HDL in the mouse serum. The drug was administered by oral gavage for 4 weeks. At the end of the 4th week, the mice were fasted but not watered for 14-16 hours, and blood was collected by removing the eyeballs. The blood was left to solidify at room temperature for 1 hour, and centrifuged at 3000 rpm for 15 minutes at 4°C. The supernatant was taken to obtain the serum sample. The mice were euthanized, dissected, and the organs required for the experiment were removed and weighed. The epididymal fat was then fixed with a special fat fixative for H&E staining. The remaining tissues were stored in an ultra-low temperature refrigerator at -80°C.
[0113] (5) Blood lipid test
[0114] The detection was performed using an enzyme marker and corresponding biochemical kits, GPO-PAP enzymatic method was used to detect TG, COD-PAP method was used to detect TC, HDL content was detected by direct method, and ELISA method was used to detect leptin (LEP) content in the serum of each group of mice, according to the instructions.
[0115] (6) Determination of liver malondialdehyde (MDA) content and superoxide dismutase (SOD) activity
[0116] Accurately weigh a certain weight of liver tissue, add an appropriate amount of pre-cooled PBS, put in steel beads and homogenize at high speed at 10000rpm and 4℃ for 5 minutes, then determine the malondialdehyde (MDA) content and superoxide dismutase (SOD) activity according to the method of the kit.
[0117] (7) HE staining of adipose tissue
[0118] The epididymal adipose tissue was fixed in a special adipose fixative, washed, dehydrated, and then waxed and embedded. It was then cut into sections and stained with hematoxylin and eosin (H&E).
[0119] (8) The results were analyzed using the one-way ANOVA method in SPSS 25.0 statistical software, and the Duncan multiple range test was used to determine the differences between the mean values. When P<0.05, it was statistically significant.
[0120] Results and Discussion
[0121] 1. Powder X-ray Diffraction (PXRD)
[0122] PXRD experiments were used to confirm the formation of HYP-MAL. The HYP-MAL powder diffraction pattern showed a different PXRD pattern from hypoxanthine and maleic acid ( Figure 1). The characteristic diffraction peaks of hypoxanthine 2θ of 10.6°, 14.2°, 17.9°, 18.4°, 19.1°, 23.7°, 26.4°, 27.1° and maleic acid 2θ of 16.9°, 17.6°, 25.4°, 26.8°, 28.2°, 28.7° disappeared, and new characteristic peaks appeared at 7.7°, 9.9°, 13.4°, 13.9°, 16.5°, 17.2°, 18.7°, 23.1°. Compared with the hypoxanthine and maleic acid samples, the new diffraction peaks appeared, indicating the presence of a new crystalline phase, and the disappearance of the characteristic peaks indicated that the sample was completely consumed. In addition, compared with the physical mixture, the cocrystal showed significant differences in the number and relative intensity of the characteristic diffraction peaks, which can be used as evidence of the formation of a new crystalline phase. In addition, the purity of HYP-MAL was confirmed by PXRD, and the results showed that the powder diffraction pattern of HYP-MAL ( Figure 1 ) and SXRD analysis simulation ( Figure 2 The middle curve e) overlaps, indicating that the purity of HYP-MAL is high.
[0123] 2. Single crystal X-ray diffraction (SXRD)
[0124] The crystal structure of the salt was determined by single crystal X-ray diffraction ( Figure 3 ), and its crystallographic data are shown in Table 2.
[0125] Table 2 Crystallographic data and refinement parameters of HYP-MAL
[0126]
[0127]
[0128]
[0129] HYP-MAL: SXRD experiments show that HYP-MAL is 1 / c space group, the asymmetric unit consists of two hypoxanthine ions and two maleate ions ( Figure 3 ). O7-H7A···O8(d: θ:177°),O10-H10···O6(d: θ:177°) are two intramolecular hydrogen bonds. The OH proton of maleic acid is transferred to hypoxanthine and forms N4 + -H4···O1 - (d: θ:172°) and N2 + -H2···O4 - (d: θ:171°) ionic bond.
[0130] 3. Thermal analysis (TG / DSC)
[0131] The thermal behavior of HYP-MAL was studied by differential scanning calorimetry and thermogravimetric analysis. DSC (Figure 4(a)) showed that the endothermic peaks of hypoxanthine and maleic acid were at 416.83°C and 157.50°C, respectively, while HYP-MAL showed endothermic peaks at 186.83°C and 404.83°C, which were different from the endothermic peaks of the individual components, indicating that they interacted to produce a new phase. In addition, the first endothermic peak of HYP-MAL showed similarity to that of MAL. We speculate that this endothermic peak indicates the thermal decomposition of the MAL component in the salt. The second signal peak is caused by the decomposition of hypoxanthine. TG (Figure 4(b)) showed that hypoxanthine decomposed immediately after melting, with a mass loss of 71.47%. However, MAL lost all its weight at approximately 190°C after melting. HYP-MAL has two weight loss steps. The first weight loss of 45.67% corresponds to the weight loss of MAL molecules (theoretical weight loss 46.04%), which is higher than the decomposition temperature of pure MAL. The second weight loss of 53.30% is consistent with the weight loss of HYP molecules. It is speculated that the sample obtained after MAL weight loss is pure HYP.
[0132] 4. Fourier Transform Infrared Spectroscopy (FTIR)
[0133] The infrared spectra of organic compounds all have stretching vibrations and various bending vibrations that are infrared-absorbed. The intensity of the red shift is related to the strength of the hydrogen bond. The stronger the intensity, the greater the red shift. The formation of hydrogen bonds will also make the vibration peaks wider. The infrared spectra of hypoxanthine, maleic acid, and hypoxanthine-maleate are shown in Figure 1. Figure 5 As shown. Hypoxanthine is at 1709.04 cm -1 The characteristic peak at 3177.5cm is the stretching vibration of C=O, forming an absorption band. -1 、3052.22cm -1 The NH stretching vibration peak appears at 1710 cm -1 The characteristic peak at 3060cm is the stretching vibration peak of C=O. -1 The OH peak is broad at 3177.5 cm-1. -1 becomes 3135.87cm -1 , the electron cloud density decreases, the characteristic peak moves to a lower wave number, forming a stronger hydrogen bond force, and the C=O in maleic acid increases from 1710cm -1 becomes 1671.91cm -1 , participates in the formation of hydrogen bonds, the hydrogen bonding mode changes, and the stretching vibration peak becomes wider.
[0134] 5. Solubility and powder dissolution test analysis
[0135] There is a correlation between solubility and bioavailability, and an increase in solubility may lead to an increase in bioavailability. The powder dissolution and equilibrium solubility of hypoxanthine and hypoxanthine-maleate were determined by HPLC. Excess solid powder was added to water and PBS at different temperatures and pH and stirred for 24 hours. The experimental results (Figure 6(a)) show that the solubility of HYP in HYP-MAL is higher than that of HYP alone, whether in water and PBS at room temperature (25°C) or 37°C. In water with pH = 6.4, the solubility of the salt is twice that of hypoxanthine. As shown in Figure 6(b), the dissolution rate of HYP in HYP-MAL is higher than that of HYP, and a "spring-parachute" effect occurs. Over time, the dissolution rate of HYP in HYP-MAL decreases slightly but is always higher than that of HYP. Solvent molecules can destroy the interaction of salts through solvent-solute interactions, thereby changing the pH of the solution, making it more likely that the solute will form hydrogen bonds with water molecules, thereby increasing solubility. Therefore, the bioavailability of a compound that is limited by solubility can be improved by salt formation.
[0136] 7. Anti-obesity effect of hypoxanthine-maleate on nutritionally obese mice
[0137] (1) Effect of HYP-MAL on the body weight of mice
[0138] As shown in Figure 7(a), after the mice were fed with a high-fat diet for four weeks (week 0), the weight of the mice in the drug group was higher than that in the blank group, indicating that the model was successfully established. During the gavage period, the weight of the mice in the model group was always higher than that in the blank group, and the weight difference between the two groups gradually increased with time. In the drug intervention group, from the beginning of drug administration, the weight of the mice in each dose group was significantly lower than that in the model group, with significant differences. The drug has a significant inhibitory effect on the increase in mouse weight, but the eutectic structure may be destroyed in the strong acidic environment of gastric fluid, and the absorption is poor, so there is no significant difference between the drug groups. Figure 7(b) and Table 3 show the weight changes of mice during the drug administration period and the difference before and after drug administration. The weight gain of the HYP-MAL low-dose group was negative, and the weight gain of the HYP-MAL medium- and high-dose groups was lower than that of other drug groups. The HYP-MAL dose groups (the subsequent HYP-MAL groups represent the HYP-MAL dose groups: HYP-MAL-L, HYP-MAL-M, HYP-MAL-H) showed a better weight loss effect. Subsequent experiments will further study the HYP-MAL group.
[0139] Table 3 Body weight changes of mice fed with high-fat diet for 4 weeks
[0140]
[0141] Table 4 Changes in mouse body weight before and after administration
[0142]
[0143]
[0144] (2) Effects of HYP-MAL on mouse viscera
[0145] Changes in the quality of the mouse liver, thymus, and fat are important indicators of obesity. Obesity caused by visceral fat is associated with hypertension, dyslipidemia, and diabetes. Figure 8 As shown. The results showed that the weights of the liver, thymus, epididymal fat, and perirenal fat of mice in the model group increased significantly, about 1.5 times, 1.4 times, 3.5 times, and 3.1 times that of the blank group, which was closely related to the intake of high-fat feed. The positive control group and each intervention group significantly reduced the weights of the liver, thymus, epididymal fat, and perirenal fat of mice. There was no significant difference in the effect of HYP-MAL on the liver weight of mice between the HYP-MAL groups, and the effect was significant compared with the model group. There was no significant difference in the effect of HYP-MAL on the thymus weight of mice between the HYP-MAL groups, and there was no significant difference compared with the blank group, which was significantly lower than the model group. The epididymal fat weight of mice in the HYP-MAL group was not significantly different from that of the blank group, and was reduced by 69%, 70%, and 60%, respectively, compared with the model group. The effect of HYP-MAL intervention on the perirenal fat weight of mice was not significantly different from that of the blank group, and was significantly lower than that of the model group, which was 28%, 35%, and 44%, respectively, of the model group.
[0146] (5) Analysis of fat tissue sections
[0147] The abdominal fat tissue sections of each group were observed under a microscope after administration. Fig. 9 As shown, the fat sections of the blank group mice showed round or polygonal fat cells with uniform cell size and blue or oblate nuclei. The fat tissue sections of the model group mice were observed to be larger in size, irregular in shape, with increased intracellular fat content, unclear cell membranes, and easy fusion of cell edges. After drug intervention, the fat tissue cells were significantly smaller and showed a recovery state. In the HYP-MAL group, the cell area was reduced and the marginal cell nuclei were reduced. After the HYP-MAL-H drug intervention, the morphology of the fat cells changed well, the number of large fat droplets was significantly reduced, and the fat cells were clearly defined and highly regular in terms of size and morphology. This shows that the drug has the effect of inhibiting fat hypertrophy and fat droplet accumulation induced by food sources, improving fat cell growth and proliferation, and reducing fat accumulation, thereby alleviating obesity symptoms.
[0148] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A hypoxanthine-maleic acid eutectic, characterized in that: Its asymmetric unit consists of two hypoxanthine ions and two maleate ions; The space group of the hypoxanthine-maleic acid eutectic is P21 / c, monoclinic system, and the specific unit cell parameters are: α=90°, β=95.862(2)°, γ=90°.
2. The hypoxanthine-maleic acid cocrystal according to claim 1, characterized in that The Cu-Kα-ray X-ray powder diffraction pattern of the hypoxanthine-maleic acid cocrystal has characteristic diffraction peaks at the following 2θ angles: 7.7±0.20°, 9.9±0.20°, 13.4±0.20°, 13.9±0.20°, 16.5±0.20°, 17.2±0.20°, 18.7±0.20°, and 23.1±0.20°.
3. The hypoxanthine-maleic acid cocrystal according to claim 1, characterized in that The Cu-Kα X-ray powder diffraction pattern of the hypoxanthine-maleic acid cocrystal is shown in FIG1 , with an error within ±0.20°.
4. The hypoxanthine-maleic acid cocrystal according to claim 1, characterized in that The differential scanning calorimetry curve of the hypoxanthine-maleic acid cocrystal shows endothermic peaks at 186.83±3.0°C and 404.83±3.0°C; Preferably, the differential scanning calorimetry spectrum of the hypoxanthine-maleic acid cocrystal is shown in FIG4( a ), and the thermogravimetric analysis spectrum is shown in FIG4( b ).
5. The hypoxanthine-maleic acid cocrystal according to claim 1, characterized in that The Fourier transform infrared spectrum of the hypoxanthine-maleic acid cocrystal is 3135.87 cm -1 There is a characteristic peak of NH in hypoxanthine at 1671.91cm -1 There is a characteristic peak of C=O in maleic acid; Preferably, the Fourier transform infrared spectrum of the hypoxanthine-maleic acid cocrystal is shown in FIG5 .
6. A method for preparing the hypoxanthine-maleic acid cocrystal according to any one of claims 1 to 5, characterized in that: The steps include: It is prepared using hypoxanthine and maleic acid as raw materials by liquid-assisted grinding.
7. The preparation method according to claim 6, characterized in that: The liquid-assisted grinding method comprises the following steps: ball-milling hypoxanthine and maleic acid in a solvent to obtain hypoxanthine-maleic acid cocrystal; The molar ratio of hypoxanthine to maleic acid is (0.9-1.1):(0.9-1.1); the solvent is selected from one or more of water, alcohols, ketones, esters, alkanes, aromatic hydrocarbons and halogenated hydrocarbons; Preferably, the solvent is selected from one or more of water, methanol, ethanol, isopropanol, ethyl acetate, acetone, methyl ethyl ketone, n-hexane and n-heptane.
8. A method for preparing the hypoxanthine-maleic acid cocrystal according to any one of claims 1 to 5, characterized in that: The steps include: It is prepared using hypoxanthine and maleic acid as raw materials and the solution evaporation method.
9. The preparation method according to claim 8, characterized in that: The solution evaporation method comprises the following steps: Recrystallize hypoxanthine and maleic acid in a solvent, and let stand to obtain hypoxanthine-maleic acid cocrystal; The molar ratio of hypoxanthine to maleic acid is (0.9-1.1):(4.9-5.1); the solvent is selected from one or more of water, alcohols, ketones, esters, alkanes, aromatic hydrocarbons and halogenated hydrocarbons; Preferably, the solvent is selected from one or more of water, methanol, ethanol, isopropanol, ethyl acetate, acetone, methyl ethyl ketone, n-hexane and n-heptane.
10. Use of the hypoxanthine-maleic acid co-crystal according to any one of claims 1 to 5 or the hypoxanthine-maleic acid co-crystal prepared by the preparation method according to any one of claims 6 to 9 in the preparation of a hypoxanthine pharmaceutical preparation; Preferably, the hypoxanthine pharmaceutical preparation has the effects of promoting fat decomposition and weight loss.
